RecruitingPhase 3NCT04949633

Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

Oxytocine Versus Prostaglandines Pour le déclenchement du Travail Des Femmes Dont le Col Est défavorable après 24 Heures de Maturation Cervicale : Essai Multicentrique randomisé de Non infériorité


Sponsor

University Hospital, Tours

Enrollment

1,494 participants

Start Date

Sep 28, 2021

Study Type

INTERVENTIONAL

Summary

Twenty-two percent of deliveries in France are induced. In cases where labor is induced and cervix is unfavorable, cervical ripening prior oxytocin administration is advised in order to reduce the risk of cesarean delivery. Cervical ripening agents, pharmacological (prostaglandins) or mechanical are administered during 24 hours. After 24 hours, most women will be either delivered or in labor but 25% of women will require further induction of labor. For 16% of women who undergo cervical ripening, whatever the cervical ripening method, the cervix remains unchanged after 24 hours. The management of these women is not consensual and depends on the maternity unit where women are cared for. This study seeks to identify the most appropriate strategy for the management of women with an unfavorable cervix after 24 hours of cervical ripening, a strategy which would be associated with the lowest maternal and perinatal morbidity but also with the best maternal satisfaction. Because both strategies are practiced in France, the trial would compare: induction of labor with oxytocin and repeated cervical ripening. The aim is to show that repeating cervical ripening is an unnecessary procedure. And more specifically that oxytocin administration is not associated with a higher caesarean delivery rate and that it reduces the time to delivery in comparison with cervical ripening with prostaglandins.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria9

  • Pregnant woman
  • ≥ 18 years old
  • With a singleton cephalic pregnancy
  • ≥37+0 weeks of gestation
  • Gestational age estimated from the first trimester ultrasound (realized between 11+0 and 13+6 weeks of gestation)
  • With a medical indication of labor with a previous pharmacological or mechanical cervical ripening of 24 hours
  • Bishop score ≤ 6 at inclusion (unfavorable cervix)
  • French health insurance policy holder
  • Written informed consent

Exclusion Criteria10

  • Any measures of legal protection
  • Prior caesarean section or uterine scar
  • Contra-indications to a vaginal delivery
  • Foetus with suspected severe congenital abnormalities
  • Pathological foetal heart rate
  • Contra-indications to ANGUSTA® (oral misoprostol, cervical ripening agent)
  • Contra-indications to PROPESS® (vaginal slow releasing system of dinoprostone, cervical ripening agent)
  • Contra-indications to PROSTINE® (vaginal gel of dinoprostone, cervical ripening agent)
  • Contra-indications for using oxytocin
  • Woman in labor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGProstaglandins

Second cervical ripening lasting a maximum of 24 hours

DRUGOxytocin

Induction of labor with oxytocin.


Locations(12)

Gynaecology-obstetrics, University Hospital, Angers

Angers, France

Gynaecology-obstetrics, University Hospital, Bordeaux

Bordeaux, France

Gynaecology-obstetrics, University Hospital, Brest

Brest, France

Gynaecology-obstetrics, University Hospital, Clermont-Ferrand

Clermont-Ferrand, France

Gynaecology-obstetrics, Hospital St Joseph, Marseille

Marseille, France

Gynaecology-obstetrics, University Hospital, Nancy

Nancy, France

Gynaecology-obstetrics, University Hospital, Nantes

Nantes, France

Gynaecology-obstetrics, University Hospital, Orléans

Orléans, France

Gynaecology-obstetrics, Port Royal Maternity Hospital, Paris

Paris, France

Gynaecology-obstetrics, University Hospital, Poitiers

Poitiers, France

Gynaecology-obstetrics, University Hospital, Saint Etienne

Saint-Etienne, France

Gynaecology-obstetrics, University Hospital, Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04949633